We have an exciting opportunity for a Senior Research Associate/Scientist. (Job Code 97 AA)

Job Summary
In this role you will work mainly in the lab under limited supervision executing experiments and process validation and verification studies. Core functions will focus on assay optimization and new assay development. On occasion, tasks may be repetitive in nature. This individual will produce and analyze data using a statistical approach and maintain laboratory notebooks in accordance with design control policies. The candidate must be able to communicate scientific results in writing and verbally to the appropriate forum.

Job Requirements

• BS/MS/PhD degree in Biology, Molecular Biology, Biochemistry or Chemistry.
• 5+ years solid experience related to Biotech/pharma/medical device industry experience with preference in medical device.
• Strong technical skill in developing and executing experiments, as well as presenting findings.
• Strong technical knowledge of process development and optimization.
• Experience with writing and doing process validations is preferred.
• Experience with the handling and manipulating of blood and/or platelets is preferred.
• Experience with protein chemistry preferred.
• Experience in a medical device, in vitro diagnostic, GLP, cGMP (QSR) or ISO environment.
• Able to communicate and present technical information (in English) effectively verbally and in writing with departmental personnel and to follow both written and verbal instructions. Able to read, understand, and adhere to Standard Operating Procedures, cGMP’s (current Good Manufacturing Practices), and other government regulations written in English. Familiar with Quality System Regulation.
• Proficient computer skills and good working knowledge of MS Office and general database usage.
• Experience running MiniTab or other statistical software a plus.

Are you the ideal candidate? What are you waiting for? Come be a part of the team at
Accumetrics and see your career grow. We are located in the Sorrento Valley area and offer great benefits and a challenging, pleasant work environment.

LOCAL CANDIDATES ONLY PLEASE

• Click here to apply

Over 150 abstracts, posters and sessions dedicated to antiplatelet therapies and platelet reactivity testing

March 26th, 2012, Chicago, IL – Accumetrics Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced that platelet reactivity testing and antiplatelet therapy choices remain at the forefront of the Annual Scientific Session of the American College of Cardiology. Over 150 sessions and posters covered antiplatelet therapy and platelet reactivity testing, including the use of newer P2Y12 inhibitors in patients with high on-clopidogrel platelet reactivity, the potential utilization of various antiplatelet dosing strategies in low weight patients, pre-surgical use of platelet reactivity testing, and the potential impact of the imminent release of generic clopidogrel to the US market in May, 2012.

“Understanding the appropriate use of all of these new treatment options is of critical importance to the practicing cardiologist,” said Dr. Paul Gurbel, Director Sinai Center for Thrombosis Research in Baltimore, MD. “We believe that platelet reactivity testing provides critical information that can help us determine the most appropriate antiplatelet treatment option. This becomes increasingly important when we have generic clopidogrel available, which may provide a cost benefit to our patients, but could potentially have a more variable effect than its branded predecessor.”

Interest in platelet reactivity testing remained high with the Accumetrics-sponsored program “Antiplatelet Therapy Choices for High Risk PCI Patients in the Era of Generic Clopidogrel: The Role of Platelet Reactivity Testing.” The program included Dr. Gurbel discussing the Platelet Reactivity Hypothesis and the personalization of antiplatelet therapy using platelet reactivity testing, followed by Dr. Matthew Price, from Scripps Clinic in La Jolla, CA, distilling the latest clinical trial data on the clinical utility of platelet reactivity testing. The program concluded with a presentation of real world experience with platelet reactivity testing in clinical practice, including incidence of poor response, treatment modifications and 30 day safety and MACE events by Dr. Richard Shlofmitz, Chairman of cardiology at St. Francis in New York.

“The high level of focus on the clinical importance of platelet reactivity testing continues to establish Accumetrics as the leader in providing clinicians with critical information for assessing the effect of a chosen treatment strategy for their PCI patients,” said Timothy I. Still, President and CEO of Accumetrics. “As we enter the era of generic clopidogrel, the VerifyNow System is poised to become a critical component in helping clinicians select the most clinically appropriate and cost-effective antiplatelet treatment solutions for cardiovascular patients across the US and throughout the world.”

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics’ VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual’s response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient®) and clopidogrel (Plavix®)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides valuable information to help physicians make informed treatment decisions. The VerifyNow P2Y12 Test is a whole blood assay used in the laboratory or point of care setting to measure the level of platelet P2Y12 receptor blockade. Additionally, it is indicated outside the US for evaluating the risk for recurrent events in cardiovascular patients.

For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Bristol Myers Squibb/Sanofi Pharmaceuticals Partnership. Effient is a registered trademark of Eli Lilly and Company.

# # #

CONTACTS:
Jakob Jakobsen
310-309-1003 (Office)
310-409-5351 (Cell)
jjakobsen@biosector2.com

Timothy I. Still
President and CEO
Accumetrics
858-404-8260
press@accumetrics.com

We have an exciting opportunity for a Buyer/Planner Manager. (Job Code 91 CDK)

Job Summary
In this role you will be responsible for the timely planning and procurement of assigned items in order to meet the production schedule within an FDA/GMP environment while complying with applicable procedures, policies, and regulations. You will also be responsible for source selection and procurement functions associated with indirect materials, services, fixed assets and tooling. This candidate will be required to perform effective negotiation of contracts while ensuring the requirements of delivery, quality and cost reduction are fulfilled. They will also develop and manage supplier relationships using their excellent oral and communication skills.

Job Requirements

• BS or BA degree in business or related discipline
• 7-8 years solid experience as a hands-on Senior level Buyer coupled with Planning experience.
• 8-10 years experience related to biotech and/or medical device procurement in an FDA/GMP manufacturing environment.
• APICS certification (CPM, CPIM, or CIRM )
• Experience with the QAD MRP program
• Experience in a medical device, in vitro diagnostic, GLP, cGMP (QSR) or ISO environment
• Ability to read blueprints and bills of material.
• Able to plan short and long-range activities and coordinate their implementation.
• Able to work in a pressured environment with constantly shifting priorities while maintaining a high and consistent service level and operating under deadline, and to exercise independent judgment in solving moderately complex problems and work with minimal supervision.

Are you the ideal candidate? What are you waiting for? Come be a part of the team at
Accumetrics and see your career grow. We are located in the Sorrento Valley area and offer
great benefits and a challenging, pleasant work environment.

LOCAL CANDIDATES ONLY PLEASE

• Click here to apply

We have an exciting opportunity for a Director of Research & Development. (Job Code 92 AA)

Job Summary
In this role you will be responsible for the design, screening and optimization of novel assays, expanding the capabilities of core technologies, and management of the Assay Development group. Individual will lead the team in the resolution of technical problems associated with production of reagents, issues with assay performance, or analysis of outside trail data. Serve as Program Manager for new assay development projects.

Job Requirements

• Masters Degree or Ph.D. in Biochemistry or Biological Sciences.
• 10+ years in the successful development of biochemical/biological assays and transfer of products to manufacturing within a GMP/ISO environment.
• Scientific approach to developing working assays for diagnostic equipment.
• Diagnostic Product Development: a strong understanding of the interaction between cellular diagnostic devices and biological reactions at a system level.
• Experience with Standard Operating Procedures, cGMP’s, Quality System Regulations in an FDA regulated environment.
• Ability to define protocols and participate in execution of product and process validations, pre-Clinical and Clinical Trials.

Are you the ideal candidate? What are you waiting for? Come be a part of the team at Accumetrics and see your career grow. We are located in the Sorrento Valley area and offer
great benefits and a challenging, pleasant work environment.

LOCAL CANDIDATES ONLY PLEASE

• Click here to apply

Company Poised to Capitalize on Four Published Guideline Recommendations, New Clinical Data, CE-Marked Prognostic Claim and Generic Clopidogrel in 2012

December 21, 2011, San Diego, CA. – Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, closes 2011 with strong support regarding the clinical value of measuring response to antiplatelet therapy. The Company also achieved several important milestones during 2011, including significant revenue growth over 2010, an expanded installed base worldwide, and a CE marked prognostic claim for its VerifyNow P2Y12 Test.

In 2011, four new published Guidelines included recommendations about platelet reactivity testing for patients on antiplatelet therapy: ACCF/AHA about UA/NSTEMI patients¹, ACCF/AHA/SCAI about PCI patients², ESC about NSTE-ACS patients³, and STS/SCA about surgical patients⁴. Included in the guidelines are recommendations that address treatment strategies based on platelet reactivity.

Throughout the year, new clinical data was published underscoring the value of platelet reactivity testing, including a pharmacodynamic analysis from the GRAVITAS trial indicating that low platelet reactivity was significantly associated with a lower risk of adverse cardiovascular events⁵. Also published was a 3,000+ patient meta-analysis demonstrating that patients with high platelet reactivity exhibited more than twice the rate of death, heart attack and stent thrombosis⁶.

Accumetrics strengthened its position as a global diagnostic leader by achieving CE marking outside the US for its VerifyNow P2Y12 Test for prognostic use in identifying patients with high residual platelet reactivity on antiplatelet therapy who are at greater risk for future cardiovascular events.

“2011 has been an important year for understanding the role of platelet reactivity testing in clinical practice,” said Matthew J. Price, MD, of the Scripps Translational Science Institute and Scripps Clinic in La Jolla, CA. “Reported findings in multiple abstract presentations and published studies, consisting in total of more than 20,000 patients, continue to confirm the strong association between high platelet reactivity and the risk of recurrent cardiovascular events, including stent thrombosis, after PCI. The 2011 guidelines now include the consideration for platelet reactivity testing in managing patients with ACS and/or PCI. Upon this foundation, we are now entering the era of generic clopidogrel, which will markedly change the cost dynamics of antiplatelet therapy. All of this emphasizes the emerging impact of platelet reactivity testing to help the physician provide the best care of our higher risk PCI patients.”

Accumetrics experienced solid growth in 2011 across all of its sales channels. The Company expects to conclude the year with roughly $21 million in annual revenue, and an expanded installed base. The VerifyNow System is used clinically by physicians in over 700 facilities in the United States and over 70 countries worldwide where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.

“With the advent of generic clopidogrel in the US in 2012, healthcare providers and payers alike will be seeking the most cost effective and clinically appropriate antiplatelet therapy for individual patients,” said Timothy I. Still, President and CEO of Accumetrics. “Accumetrics is pleased to offer an innovative and cost-effective point-of-care solution that addresses the need for clinicians to better understand the effect of their treatment decisions, ultimately benefitting public health.”

About Accumetrics
Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics’ VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual’s response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient®) and clopidogrel (Plavix®)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides valuable information to help physicians make informed treatment decisions. The VerifyNow P2Y12 Test is a whole blood assay used in the laboratory or point of care setting to measure the level of platelet P2Y12 receptor blockade. Additionally, it is indicated outside the US for evaluating the risk for recurrent events in cardiovascular patients.

For more information about the Company and its products, visit http://www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Bristol Myers Squibb/Sanofi Pharmaceuticals Partnership. Effient is a registered trademark of Eli Lilly and Company.

# # #

CONTACTS:
Jakob Jakobsen
310-309-1003 (Office)
310-409-5351 (Cell)
jjakobsen@biosector2.com

Timothy I. Still
President and CEO
Accumetrics
858-404-8260
press@accumetrics.com

—————————————————-
¹ Wright RS, et al. J Am Coll Cardiol 2011; 57:1920-1959
² Levine, GN. et al. J. Am. Coll. Cardiol. Published online Nov 7, 2011; doi:10.1016/j.jacc.2011.08.007
³ Hamm, CW. et al. Eur Heart J (2011) first published online August 26, 2011 doi:10.1093/eurheartj/ehr236
⁴ Ferraris, VA. et al. Ann Thorac Surg. 2011 Mar;91(3):944-82
⁵ Price, MJ. et al Circulation. 2011;124:1132-1137
⁶ Brar, S et al. J Am Coll Cardiol 2011;58:1945–54

Platelet Reactivity Levels Significantly Associated with 30-Day Outcomes in the Largest Platelet Reactivity Study To Date

November 9th, 2011, San Diego, CA – Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced that patients with high platelet reactivity, i.e. high PRU values as measured by the Accumetrics VerifyNow P2Y12 Test, exhibited an approximately four times higher rate of stent thrombosis than patients without high platelet reactivity, as seen in the ADAPT-DES registry. The 30-day results from the 8,500+ patient registry were presented today at the 2011 TCT conference in San Francisco. The VerifyNow P2Y12 Test is used to measure the level of P2Y12 receptor blockade and the antiplatelet effect of medications such as clopidogrel and prasugrel (Plavix® and Effient®).

“Stent thrombosis is a rare but catastrophic event that patients are at risk for following a stent procedure,” said Dr. Paul Teirstein, Chief of Cardiology, Scripps Clinic, La Jolla, CA. “This latest data set tells us that many of these events are attributable directly to platelet reactivity,” he added. “Platelet reactivity testing provides additional information to allow us as physicians to understand the treatment effect in our effort to reduce the risk of stent thrombosis in these patients.”

The findings from ADAPT-DES are consistent with other recent publications, including the GRAVITAS pharmacodynamic analysis ¹ and a 3,000+ patient meta-analysis of platelet reactivity testing ², that have demonstrated a significant association between platelet reactivity and recurrent cardiovascular events . Also just published is the 2011 ACCF/AHA/SCAI PCI guideline update ³, which provides guidance on which patients to test, and treatment options for patients with high on-clopidogrel platelet reactivity.

“2011 has marked a tremendous surge in the validation of the clinical role of platelet reactivity testing,” said President and CEO of Accumetrics, Timothy I. Still. “With the inclusion of platelet function testing in four separate clinical guidelines this year, and as we enter the era of generic Plavix in the US, there is an even greater need for more information to help physicians determine the most cost-effective treatment strategies while providing the highest quality patient care.”

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics’ VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual’s response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient®) and clopidogrel (Plavix®)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides valuable information to help physicians make informed treatment decisions. The VerifyNow P2Y12 Test is a whole blood assay used in the laboratory or point of care setting to measure the level of platelet P2Y12 receptor blockade. Additionally, it is indicated outside the US for evaluating the risk for recurrent events in cardiovascular patients. The VerifyNow System is used by physicians in over 700 facilities in the United States and over 70 countries worldwide where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke. For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis. Effient is a registered trademark of Eli Lilly and Company.

# # #

CONTACTS:
Jakob Jakobsen
310-309-1003 (Office)
310-409-5351 (Cell)
jjakobsen@biosector2.com

Timothy I. Still
President and CEO
Accumetrics
858-404-8260
press@accumetrics.com

—————————————————-
¹ Price, MJ. et al Circulation. 2011;124:1132-1137
² Brar, S et al. J Am Coll Cardiol 2011;58:1945–54
³ Levine, GN. et al. J. Am. Coll. Cardiol. published online Nov 7, 2011

Stent Patients with High Platelet Reactivity Had Twice the Rate of Cardiovascular Events

SAN DIEGO October 26th, 2011 – Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced that results from a patient-level meta-analysis of more than 3,000 stent patients have been published in the Journal of the American College of Cardiology ¹. Patients in the study with high platelet reactivity, as measured by the Accumetrics’ VerifyNow P2Y12 Test, exhibited more than twice the rate of cardiovascular death, heart attack and stent thrombosis over 2 years compared to patients without high platelet reactivity. The VerifyNow P2Y12 Test is used to measure a patient’s platelet reactivity and the antiplatelet effect of medications such as clopidogrel and prasugrel (Plavix® and Effient®).

“The results from this meta-analysis provide further insight into the established relationship between platelet reactivity and clinical outcomes, and give greater clarity to a target for identifying patients at risk,” said Somjot Brar, MD, of Kaiser Permanente in Los Angeles, CA, and lead author of the article. “The additional information provided by platelet reactivity testing, on top of our traditional clinical and procedural risk factors, can allow us to better classify patients that may be at greater risk of recurrent cardiovascular events after a stent procedure.”

2011 marks a banner year for advancing the understanding and progression of the role of platelet reactivity testing in clinical practice. With the inclusion of testing into 3 major guidelines (ACCF/AHA, STS/SCA and ESC) and numerous published reports, including the recent pharmacodynamic analysis of GRAVITAS ², platelet reactivity testing and personalized antiplatelet therapy continue to be in the forefront of cardiovascular medicine.

“The new publications and guideline recommendations have greatly increased clinical demand for the VerifyNow System as physicians move towards a more individualized approach to cardiovascular medicine,” said President and CEO of Accumetrics, Timothy I. Still. “As we progress towards the era of generic Plavix in the US along with a broader array of new and more expensive antiplatelet agents, there is greater need for more information to help physicians determine the most cost-effective treatment strategies and provide the highest quality patient care.”

The VerifyNow P2Y12 Test is the first clinically available, rapid and easy-to-use point-of-care system for measuring the level of P2Y12 receptor blockade. Additionally, it is indicated outside the US for evaluating the risk for recurrent events in cardiovascular patients. The VerifyNow System is used by physicians in over 700 facilities in the United States and over 70 countries worldwide where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics’ VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual’s response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient®) and clopidogrel (Plavix®)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides valuable information to help physicians make informed treatment decisions. For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis. Effient is a registered trademark of Eli Lilly and Company.

# # #

CONTACTS:
Jakob Jakobsen
310-309-1003
jjakobsen@biosector2.com

Timothy I. Still
President and CEO
Accumetrics
858-404-8260
press@accumetrics.com

—————————————————-
¹ Brar, S et al. J Am Coll Cardiol 2011;58:1945–54
² Price, MJ. et al Circulation. 2011;124:1132-1137

Clinical Role of Platelet Reactivity Testing Gains Additional Support with Third Guideline Recommendation by a Medical Society in 2011

SAN DIEGO, September 7th, 2011 – Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that a new recommendation (IIb-B) to consider platelet function testing has been incorporated in the European Society of Cardiology (ESC) Guidelines. Published in the European Heart Journal¹, the guidelines also include a second recommendation that addresses modifying treatment strategies based on platelet reactivity measurements in selected cases (IIb-B).

“We know that high on treatment platelet reactivity is an established risk factor for major cardiac events,” stated Dr. Marco Valgimigli from the Cardiovascular Institute in Ferrara, Italy. “With the development of new, more potent antiplatelet treatment strategies, and the continued validation of point of care platelet reactivity tests, we as physicians can utilize platelet reactivity measurements as a tool to ensure we provide our patients the most appropriate and cost-effective treatment options. This individualized approach of combining traditional risk factors with an understanding of the effect of our treatment decisions is something that we had already implemented at the Cardiovascular Institute.”

The inclusion of platelet function testing in the ESC guidelines coincides with the recent publication of a pharmacodynamic analysis of GRAVITAS trial data, which demonstrated a 50% reduction in cardiovascular risk when patients achieved a low level of platelet reactivity as measured by the VerifyNow P2Y12 Test². Further, this closely follows the addition of platelet reactivity testing to the 2011 ACC/AHA ACS/NSTEMI guideline update, as well as inclusion within the 2011 STS blood conservation guidelines for use as part of a pre-surgical risk assessment strategy.

“With the recommendations from the ESC and several other societies, the clinical evidence for point of care platelet reactivity testing continues to grow,” said Accumetrics President and CEO, Timothy I. Still. “These guidelines further position the VerifyNow System as the global market leader for providing critical information to aid physicians in determining if a patient has not received the expected effect of their antiplatelet therapy, and if the patient is at increased risk for recurrent cardiovascular events.”

The VerifyNow System is the first clinically available, rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents. Additionally, it is indicated outside the US for evaluating the risk for recurrent events in cardiovascular patients. The System is widely used in various clinical settings where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics’ VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual’s response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient®) and clopidogrel (Plavix®)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides valuable information to help physicians make informed treatment decisions. For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis. Effient is a registered trademark of Eli Lilly and Company.

# # #

CONTACT:
Jakob Jakobsen
310-309-1003
jjakobsen@chandlerchiccocompanies.com

Timothy I. Still
President and CEO
Accumetrics
858-404-8260
press@accumetrics.com

Ad de Waard
VP International Sales and Marketing
Accumetrics
press@accumetrics.com

—————————————————-
¹ Hamm, CW. Et al. Eur Heart J (2011) first published online August 26, 2011 doi:10.1093/eurheartj/ehr236
² Price, MJ. et al Circulation. 2011;124:1132-1137.

Following Stent Placement, Low Platelet Reactivity at Time of Discharge and After 30 Days Leads to 50% Reduction in Cardiovascular Events

SAN DIEGO, August 29th, 2011 – Data announced today at the European Society of Cardiology (ESC) Congress in Paris and simultaneously published in Circulation[1] show that stent patients exhibited a 50% reduction in cardiovascular death, heart attack and stent thrombosis over 6 months when they achieved low platelet reactivity, as measured by the Accumetrics’ VerifyNow P2Y12 Test, at discharge and 30 days post-procedure.  The VerifyNow P2Y12 Test is used to measure a patient’s platelet reactivity and the antiplatelet effect of medications such as clopidogrel or prasugrel (Plavix^® and Effient^®).

With this analysis, GRAVITAS is the largest multicenter randomized trial to demonstrate that reduced levels of platelet reactivity while receiving clopidogrel were independently associated with a lower risk of cardiovascular events, even after elective (non-urgent) stent procedures.  Further, this marks the second recent published report[2]highlighting the clinical significance of platelet reactivity measurements not only within the first 24-48 hours of a stent procedure, but also at 30 days after the procedure is completed.  This demonstrates the importance of continuing to assess a patient’s platelet reactivity at follow-up within the hospital or outpatient settings.